Table 4.
Overview complication prospective cohort studies
| Maverick® | Acroflex® | ProDisc® | Charité® | Total range (%) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Huec et al. [37–39] (N = 64) | Fraser et al. [40] (N = 28 ♂14) | Bertagnoli et al. [27] (N = 108) | Tropiano et al. [28] (N = 53) | Tropiano et al. [29] (N = 55, ♂30) | Bertagnoli et al. [30] (N = 104, ♂47) | Bertagnoli et al. [31] (N = 25, ♂15) | Chung et al. [32] (N = 36) | Siepe et al. [33] (N = 99, ♂39) | Ogon et al. [35] (N = 34) | Zeegers et al. [21] (N = 50, ♂20) | Regan [22] (N = 100) | Lemaire et al. [23] (N = 100 ♂41) | Ross et al. [24] (N = 160 ♂62) | Gioia et al. [25] (N = 36 ♂13) | Warachit [26] (N = 43) | ||
| Approach-related | 11 (17.2%) | 1 (7.1%)a | 4 (8.7%)a | 1 (2.1%)a | 1 (6.7%)a | 2 (5.5%) | 3 (6.1%)a | 2 (5.9%) | 4 (11.0%)a | 3 (4.5%)a | 22 (18.7%)a | 2 (10.5%)a | 2.1–18.7 | ||||
| Prosthesis related | 11 (39.3%) | 3 (5.7%) | 3 (12.0%) | 2 (2.0%) | 1 (2.0%) | 5 (5.0%) | 2 (2.0%) | 9 (5.6%) | 2 (5.6%) | 3 (7.0%) | 2.0–39.3 | ||||||
| Treatment related | 14 (21.9%) | 4 (14.3%) | 2 (3.8%) | 5 (9.0%) | 4 (3.8%) | 3 (8.3%) | 11 (11.1%) | 1 (2.9%) | 31 (62.0%) | 4 (4.0%) | 10 (10.0%) | 3 (1.9%) | 3 (8.3%) | 1.9–62.0 | |||
| General surgical related | 1 (1.6%) | 1 (3.6%) | 1 (1.0%) | 1 (1.8%) | 1 (4.0%) | 1 (1.0%) | 1 (2.9%) | 7 (14.0%) | 1 (1.0%) | 19 (11.9%) | 4 (11.1%) | 1.0–14.0 | |||||
| Total of complications | 26 (40.6%) | 17 (64.3%) | 1 (1.0%) | 5 (9.4%) | 10 19.5%) | 5 (5.9%) | 5 (22.7%) | 5 (13.8%) | 17 (20.2%) | 4 (11.8%) | 44 (91.0%) | 9 (9.0%) | 16 (17.5%) | 53 (38.1%) | 11 (35.5%) | 3 (7.0%) | 1.0–91.0 |
| Reoperation at index level | 8 (28.6%) | 3 (5.7%) | 3 (5.5%) | 1 (1.0%) | 1 (4.0%) | 8 (8.1%) | 1 (2.9%) | 7 (14.0%) | 7 (7.0%) | 5 (5.0%) | 12 (7.5%) | 5 (13.9%) | 1 (2.3%) | 1.0–28.6 | |||
aRetrograde ejaculation calculated for men only